Teva Pharmaceutical Industries (TEVA) Amortization - Intangibles (2018 - 2026)

Teva Pharmaceutical Industries (TEVA) has 9 years of Amortization - Intangibles data on file, last reported at $22.0 million in Q2 2026.

• Quarterly Amortization - Intangibles fell 47.62% year-over-year to $22.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $126.0 million (down 53.85% YoY) and the FY2025 annual result came in at $259.0 million, up 3.19% from the prior year.
• Amortization - Intangibles rose to $22.0 million in Q2 2026, from $8.0 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $178.0 million in Q1 2023 to a low of $8.0 million in Q1 2026.
• A 5-year average of $69.2 million and a median of $61.0 million in 2023 frame the typical range for Amortization - Intangibles.
• Annual changes were most pronounced in 2025 — Amortization - Intangibles surged 128.57% — and 2026, when it slumped 93.39%.
• Tracing TEVA's Amortization - Intangibles over 5 years: stood at $132.0 million in 2022, then plunged by 53.79% to $61.0 million in 2023, then surged by 34.43% to $82.0 million in 2024, then slumped by 60.98% to $32.0 million in 2025, then plunged by 31.25% to $22.0 million in 2026.
• The last three Amortization - Intangibles figures came in at $22.0 million (Q2 2026), $8.0 million (Q1 2026), and $32.0 million (Q4 2025), per Business Quant data.